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Abstract
Introduction: Early identification of Alzheimer’s disease (AD) is needed both for clinical trials and in clinical practice. In this
study, we compared brief cognitive tests and cerebrospinal fluid (CSF) biomarkers in predicting conversion from mild
cognitive impairment (MCI) to AD.
Methods: At a memory clinic, 133 patients with MCI were followed until development of dementia or until they had been
stable over a mean period of 5.9 years (range 3.2–8.8 years). The Mini-Mental State Examination (MMSE), the clock drawing
test, total tau, tau phosphorylated at Thr181 (P-tau) and amyloid-b1–42 (Ab42) were assessed at baseline.
Results: During clinical follow-up, 47% remained cognitively stable and 53% developed dementia, with an incidence of
13.8%/year. In the group that developed dementia the prevalence of AD was 73.2%, vascular dementia 14.1%, dementia
with Lewy bodies (DLB) 5.6%, progressive supranuclear palsy (PSP) 4.2%, semantic dementia 1.4% and dementia due to
brain tumour 1.4%. When predicting subsequent development of AD among patients with MCI, the cognitive tests classified
81% of the cases correctly (AUC, 0.85; 95% CI, 0.77–0.90) and CSF biomarkers 83% (AUC, 0.89; 95% CI, 0.82–0.94). The
combination of cognitive tests and CSF (AUC, 0.93; 95% CI 0.87 to 0.96) was significantly better than the cognitive tests
(p=0.01) and the CSF biomarkers (p=0.04) alone when predicting AD.
Conclusions: The MMSE and the clock drawing test were as accurate as CSF biomarkers in predicting future development of
AD in patients with MCI. Combining both instruments provided significantly greater accuracy than cognitive tests or CSF
biomarkers alone in predicting AD.
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Introduction
The early identification of Alzheimer’s disease (AD) is becoming
increasingly important so that the correct care and follow-up can
be initiated [1,2]. Many on-going studies address disease-
modifying treatments for AD, and in the future it will probably
be important to identify AD patients very early in order to
commence these treatments in time [3]. AD is generally preceded
by an incipient preclinical phase [4], which progresses to mild
cognitive impairment (MCI) [5] and finally to dementia [6]. MCI
is not only caused by incipient dementia, but has many different
causes and varying patterns of progression. To identify patients
with AD at an early stage, it is therefore important to identify
specifically those MCI patients who will later convert to AD.
A most successful biomarker-based method of predicting the
conversion from MCI to AD has been the analysis of cerebrospinal
fluid (CSF) and in particular total tau (tau), tau phosphorylated at
Thr181 (P-tau) and the 42-amino-acid isoform of amyloid-b1–42
(Ab42). These analyses have provided classification accuracies of
around 80% or even more. [7–9] Unfortunately, these analyses are
not available everywhere, and are unlikely to become a standard
procedure because of the increasing prevalence of dementia,
especially in developing countries, and the fact that the majority of
patients must be evaluated in primary care.
Another way to predict AD is by administering brief cognitive
tests. The most commonly used cognitive tests for dementia
screening are the Mini-Mental State Examination (MMSE) and
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ability to predict AD, but with highly varying results ranging from
zero predictive ability to values similar to those of CSF [11–16].
One way to establish their predictive ability is compare their
performance with well-validated CSF biomarker. It would also be
useful if the brief cognitive tests were as accurate as CSF
biomarkers in predicting AD, because cognitive tests are available
everywhere, can be administered quickly, are very cheap and well
tolerated by patients. In addition to comparing the MMSE and
clock drawing test with CSF, it would be useful to know whether
they complement one another, providing additional diagnostic
value, especially in clinics that use both CSF analysis and cognitive
tests.
To our knowledge, no previous article has compared the clock
drawing test and the MMSE with CSF biomarkers for the
prediction of AD. Only two different studies have ever reported on
any kind of cognitive test and CSF biomarkers in the same MCI
study; a Swedish MCI study and the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) [11,17–19]. The Swedish MCI
paper did not have the aim of comparing the methods and the
ADNI papers only followed the patients for about two years and
did not examine brief cognitive tests suitable for primary care.
The primary aim of this study was to compare the abilities of the
MMSE and the clock drawing test with CSF biomarkers to predict
AD among MCI patients. Our secondary aim was to investigate
the additional diagnostic value achieved by combining the
cognitive tests with CSF biomarkers.
Materials and Methods
The MCI Population
This study was conducted at the Memory Clinic of Ska ˚ne
University Hospital in Malmo ¨, Sweden. The MCI cohort
consisted of patients referred to the clinic between October 2000
and January 2006. Most patients were referred from primary care
units, but some referrals came from other clinics at the hospital.
The specific procedures of this cohort have been described in
greater detail elsewhere [20]. At the initial visit, all patients were
assessed by physicians experienced in dementia disorders, and
underwent thorough physical, psychiatric and neurological ex-
aminations, as well as an interview that focused on their cognitive
symptoms and ADL function. The patients also underwent
a computed tomography or magnetic resonance imaging of the
brain, lumbar puncture, cognitive tests and routine blood analysis,
including assessment of their apolipoprotein E (APOE) genotype.
The MCI criteria proposed by Petersen and colleagues were
applied [21], i.e. 1) memory complaints of the patient, but
preferable also acknowledged by an informant; 2) objective
memory impairment in relation to age and education, assessed
by the physician; 3) a relatively preserved general cognition based
on the physicians structural interview and a MMSE score of at
least 24 points; 4) intact or very slightly impaired ADL; and 5) not
fulfilling the DSM-IIIR criteria for dementia [22].
In the present study, 133 patients with MCI at baseline were
included. The patients were followed over time with repeated
clinical visits, until development of either a specific type of
dementia or until they had been cognitively stable (stable MCI) for
5.9 years (range 3.2–8.8 years). AD was diagnosed as probable AD
according to NINCDS-ADRDA [23], vascular dementia (VaD;
either probable VaD according to NINDS-AIREN [24] or
subcortical VaD according to Erkinjuntti and colleagues [25]) or
dementia with Lewy bodies (DLB) according to the McKeith
criteria [26]. A consensus group of three study physicians
experienced in dementia disorders (OH, JH and LM) later
determined all diagnoses. The physicians were blinded to the CSF
and cognitive test data collected on the initial visit.
The Regional Ethics Committee in Lund, Sweden, approved
the study design and the consent. All patients gave their written
informed consent. The data were analyzed anonymously.
The MMSE and the Clock Drawing Test
The maximum score of the MMSE is 30 and the test consists of
the following parts: time and place orientation (10 points), word
registration (3 points), attention (5 points), delayed word recall (3
points), various verbal tasks (8 points) and visuo-construction (1
point) [27]. The attention part was administered using the serial 7s
task. Spelling backwards was only used if the patient could not
perform serial 7s. Apart from the total MMSE score, the combined
score of orientation and delayed word recall was also used as
a variable, hereafter referred to as MMSE (orientation & recall).
These two parts have previously been shown to be the best MMSE
predictors of future AD [15,16,28].
The clock drawing test was administered on a blank piece of
paper and the patients were instructed to draw the face of a clock
with all the numbers on it and set the time to 10 after 11. The test
was scored according to Shulman et al. [29], since this scoring
method has been better at predicting AD compared to other
scoring methods [11]. Five points were given for a perfect clock
and 0–4 points depending on the severity of the errors.
CSF Analysis
CSF was collected at baseline in polypropylene tubes and gently
mixed to avoid gradient effects. All samples were centrifuged
within 30 minutes at +4uC at 2000 g for 10 min to remove cells
and debris. Samples were stored in aliquots at 280uC pending
biochemical analysis. The procedure used and the analysis of the
CSF followed the Alzheimer’s Association Flow Chart for lumbar
puncture [30]. The Luminex xMAP technology was used to
determine the levels of tau, Ab42 and P-tau [31]. In addition to
tau, Ab42 and P-tau, the ratio of Ab42/tau was tested as a separate
variable in the logistic regression models since it previously has
shown high predictive accuracy in this cohort [20]. Lumbar
puncture was only conducted at the initial visit.
Statistical Analysis
The categorical variables sex and presence of the APOE e4
allele were analysed using the x
2 test. All non-categorical
variables were compared using the Kruskal-Wallis one-way
analysis of variance. If this test was significant, Mann-Whitney
U test was performed. Sensitivity and specificity were calculated
using the receiver operating characteristic (ROC) curve analysis.
ROC curve analysis was first performed on single CSF and
cognitive test variables. The cut-off which produced the highest
Youden index (sensitivity + specificity –1) was chosen. The
method of DeLong et al. (implemented in MedCalc) was used
to compare the ROC curves of single variables and the logistic
regression models [32].
The ability of the CSF biomarkers and cognitive tests to predict
dementia and AD was also examined with logistic regression
analysis using the backward likelihood ratio (LR) method. Sex and
age were adjusted for in the regression models. Before entering the
clock drawing data into the regression models this variable was
dichotomized because of the small number of patients at the more
impaired levels. The original cut-off by Shulman of ,4 points was
used [29,33].
The variables were screened for multicollinearity using the
Spearman correlation, because multicollinearity can cause un-
stable models. There were strong correlations between the MMSE
Comparison of Cognitive Tests and CSF in MCI
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tau and Ab42/tau (r 20.88; p,0.001). The models that included
tau and MMSE (orientation & recall) produced better accuracies
than the models with Ab42/tau and the MMSE. Therefore, the
latter two variables were removed to reduce collinearity. Ab42 was
entered separately both as a continuous variable and as
a dichotomised variables (cut-off according to the highest Youden
index, which was ,208). The variable that classified most patients
correctly was used.
To compare the models that included the CSF variables with
the models that included the cognitive test variables, the
probabilities of each model were saved as a new variable (a value
between 0 and 1 for each individual). These variables were then
used to plot ROC curves and to compare the areas under the
curves (AUCs). The comparison of AUCs has previously been used
to compare logistic regression models [12].
A p value of ,0.05 was considered statistically significant
(hereafter referred to as ‘‘significant’’). The ROC analyses,
including the comparisons of the AUCs, were performed with
MedCalc version 11.5.1 (MedCalc Software, MariaKerke, Bel-
gium). All other analyses were performed with SPSS software,
version 19.0.0 (SPSS Inc., Chicago, IL).
Results
Of the 133 patients with MCI at baseline, 53.4% (71 patients)
developed dementia and 46.6% (62 patients) remained stable
during the mean follow-up period of 5.9 years (range 3.2–8.8
years). The dementia incidence was 13.8% per year and 10.1% for
AD specifically. Among those who developed dementia, the
prevalence of AD was 73.2% (52 patients), VaD 14.1% (10
patients), DLB 5.6% (4 patients), progressive supranuclear palsy
(PSP) 4.2% (3 patients), semantic dementia 1.4% (1 patient) and
dementia due to brain tumour (according to DSM-IV [34]) 1.4%
(1 patient). The patients with VaD, DLB, PSP, semantic dementia
and dementia due to brain tumour, were grouped as ‘‘MCI-other
dementias’’. The demographics of the different groups are shown
in table 1. All CSF and cognitive test variables differed significantly
between patients with MCI who subsequently developed AD
(MCI-AD) and cognitively stable patients with MCI (stable MCI).
Patients with MCI-other dementias had lower MMSE score, but
not MMSE (orientation & recall) score, compared to stable MCI.
Sex, MMSE, MMSE (orientation & recall), tau, Ab42, P-tau and
Ab42/tau differed significantly between MCI-AD and MCI-other
dementias (Table 1).
Prediction of AD with ROC Curve Analysis
The sensitivity and specificity of each CSF and cognitive test
variable are shown in Table 2. The variable with the best AUC
to differentiate MCI-AD from stable MCI and MCI-other
dementias was Ab42 (AUC 0.84, 95% CI 0.77–0.90), followed
by MMSE (orientation & recall) (AUC 0.82, 95% CI 0.74–
0.88). The MMSE, MMSE (orientation & recall) and all CSF
variables had a significantly better AUC than the clock drawing
test. Otherwise there were no significant differences between the
variables.
The best combination of CSF biomarkers was the tau/Ab42
ratio. At ,1.6 the sensitivity was 74% and the specificity 92%
(AUC 0.88, 95% CI 0.81–0.93). A combined MMSE (orientation
& recall) score and clock drawing score of less than 15 points
produced a sensitivity of 71% and a specificity of 84% (AUC 0.84,
95% CI 0.77–0.90). These two combinations did not differ
significantly (p=0.44).
Prediction of AD with Logistic Regression Analysis
When predicting AD compared with stable MCI and MCI-
other dementias, the MMSE (orientation & recall), clock drawing
(dichotomised at ,4 points) and age classified 81% of the cases
correctly (AUC 0.85, 95% CI 0.77–0.90). Ab42, tau and age
classified 83% correctly (AUC 0.89, 95% CI 0.82–0.94). No
significant difference was found between the AUCs obtained using
cognitive tests or CSF biomarkers (p=0.36, Table 3). In the
combined model, MMSE (orientation & recall), Ab42 (dichot-
omised at ,208), tau and clock drawing (dichotomised at ,4
points) classified 85% of the patients correctly (AUC 0.93, 95% CI
0.87–0.96). The AUC of the combined model was significantly
greater than the AUC of the CSF model (p=0.04) and the
cognitive test model (p=0.01). Therefore, the combination of
cognitive tests and CSF analysis contributed significant added
diagnostic value to using CSF biomarkers or cognitive tests
separately, when predicting AD (Table 3, Fig. 1).
Discussion
In this study, we found that there was no significant
difference between the brief cognitive tests and the CSF
biomarkers in predicting progression to AD. The combination
of cognitive tests and CSF biomarkers was significantly better
than both CSF biomarkers and cognitive tests used separately,
thus providing a small added diagnostic value in predicting AD
(Table 3, Fig. 1).
The Cognitive Tests
In agreement with our results, previous studies have also found
that the orientation and delayed recall parts of the MMSE are
good at predicting specifically AD [15,16,28]. The reason MMSE
(orientation & recall) can identify specifically MCI-AD among
MCI-other dementias and stable MCI is that patients with
subcortical dementias tend to produce relatively high scores on
these parts of the MMSE, while AD deteriorate early in
orientation and memory [35,36].
Clock drawing has generally produced low predictive accura-
cies, consistent with our results, which have been significant in
some studies [37,38] but not in others [11,14,39]. It is possible that
the clock drawing test would have performed better if a clock
copying task had been used, since clock copying compared to clock
drawing can discriminate between AD and subcortical dementias
such as DLB and VaD [40–42].
The CSF Biomarkers
A meta-analysis has investigated the ability of P-tau to separate
stable MCI from MCI-AD. The pooled data from six studies
indicated a sensitivity of 81% and a specificity of 65% [43], which
are slightly lower predictive accuracies compared to the present
study (sensitivity 67%, specificity 86%; Table 2). There is no meta-
analysis for Ab42 and Tau that examines progression of MCI, but
Bloudek et al. pooled data from 15–24 studies to compare AD with
other dementias and stable MCI. They found a sensitivity and
specificity to be 73% and 72%, respectively, for Ab42, and 77%
and 74%, respectively, for tau. Both results are lower compared to
the present study (Table 2). The better predictive accuracies in our
study might be explained by the long follow-up period, which
increases the likelihood of a correct diagnosis, and by the fact that
the cut-offs were optimised for the present population.
Logistic Regression Analyses
When comparing the AUCs of the CSF and cognitive tests
models, no significant difference was found (p=0.36). Thus, in this
Comparison of Cognitive Tests and CSF in MCI
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good as the CSF biomarkers at identifying MCI-AD and
differentiating it from MCI-other dementias and stable MCI.
When combining the cognitive tests and the CSF biomarkers,
85% of the cases were classified correctly and the AUC of 0.93 was
significantly better than the cognitive test model (p=0.01) and the
CSF model (p=0.04). Therefore, the combination of the MMSE,
the clock drawing test and CSF biomarkers provided significant
additional diagnostic value compared to using either method alone
(Table 3; Fig. 1). Although statistically significant, it should be
noted that the combined model only classified additionally 4% (5
patients) correctly compared to the cognitive tests and 2% (3
patients) compared to the CSF biomarkers.
In terms of clinical usage, CSF markers and cognitive tests
should of course never be used alone to diagnose AD, but as
a complement to strengthen the diagnosis. For this purpose, both
instruments have been incorporated in the new clinical criteria for
AD [5,6].
Comparison of Cognitive Tests and Biomarkers in Other
Studies
To the best of our knowledge, only three previous papers have
examined both CSF analysis and cognitive tests to predict the
follow-up diagnoses of MCI [11,18,19]. In one of the papers, it
was not investigated statistically if the combination provided
significant added value for predicting AD [11]. The other two
papers are from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) study. In one of them, Llano et al. followed MCI patients
during 12 months and found that the ADAS-cog (a 30–40 minutes
long cognitive test battery) was equal to MRI of the brain and CSF
analysis [19]. In the other, Ewers et al. found that the combination
of different independent variables provided no significant added
value [18]. In fact, they found that any one single variable was just
as good as any combination of CSF, cognitive test and volumetric
atrophy measurements. Although we had enough power in our
study to detect a significant added value when combining cognitive
tests and CSF biomarkers, the difference was quite small and our
Table 1. Baseline variables.
Variable Stable MCI (N=62) MCI-AD (N=52)
MCI-Other
dementias (N=19) Significant difference
Age, mean (range) 69.8 (55–85) 75.3 (55–87) 71.2 (59–83) MCI-AD . Stable MCI*** MCI-AD . MCI-Other*
Sex, female 55% 70% 42% MCI-AD . MCI-Other*
APOEe4, $ one allele 45% 76% 63% MCI-AD . Stable MCI***
MMSE, mean 6 SD 28.161.2 26.161.5 27.162.0 Stable MCI . MCI-AD*** Stable MCI . MCI-Other*
MMSE (O & R), mean 6 SD 11.461.1 9.661.4 10.961.3 Stable MCI . MCI-AD*** MCI-Other . MCI-AD***
Clock drawing, mean 6 SD 4.760.6 4.061.0 4.360.9 Stable MCI . MCI-AD***
Tau, mean 6 SD 78.1644.3 141.5671.2 78.8639.5 MCI-AD . Stable MCI*** MCI-AD . MCI-Other**
Ab42, mean 6 SD 244.9663.7 155.2657.9 214.7664.8 MCI-Other . MCI-AD*** Stable MCI . MCI-AD***
P-tau, mean 6 SD 30.0616.6 49.0622.5 26.0611.5 MCI-AD . Stable MCI*** MCI-AD . MCI-Other***
Ab42/Tau, mean 6 SD 4.061.9 1.561.2 3.261.5 MCI-Other . MCI-AD*** Stable MCI . MCI-AD***
*p,0.05;
**p,0.01;
***p,0.001.
AQT = A Quick Test of Cognitive Speed; MCI-AD = MCI patients who progress to AD; MCI-Other dementias = MCI patients who progress to other dementias than AD;
MMSE (O & R) = the orientation and delayed word recall parts of the MMSE; SD = standard deviation.
MMSE, MMSE (O&R), Clock drawing, Ab42 and Ab42/Tau: A lower value is pathological.
AQT, Tau and P-tau: A higher value is pathological.
There were significant differences among the groups for all variables (Kruskal-Wallis).
doi:10.1371/journal.pone.0038639.t001
Table 2. Comparison of single variables for predicting follow-up diagnoses (ROC curve analysis).
MCI-AD (N=52) compared with Stable MCI and MCI-other dementias (N=81)
Variable AUC (95% CI) Cut-off Sensitivity, % (95% CI) Specificity, % (95% CI)
MMSE 0.79 (0.71–0.86)* ,27 points 62 (47–75) 84 (74–91)
Clock drawing 0.67 (0.58–0.75) ,4 points 44 (31–59) 86 (77–93)
MMSE (O & R) 0.82 (0.74–0.88)** ,10 points 54 (40–68) 94 (86–98)
Tau 0.81 (0.73–0.87) * .87 pg/ml 80 (66–90) 72 (61–82)
Ab42 0.84 (0.77–0.90)** ,208 pg/ml 90 (79–97) 69 (58–79)
P-tau 0.79 (0.72–0.86)* .39 pg/ml 67 (53–80) 86 (77–93)
*p,0.05; ** p,0.01; compared with AUC of clock drawing.
The cut-offs were chosen to yield the highest Youden index.
Clock drawing was scored according to Shulman {Shulman, 2000 #36}.
CI= Confidence interval, MMSE (O & R) = The orientation and delayed word recall parts of the MMSE.
doi:10.1371/journal.pone.0038639.t002
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suggest that roughly the same patients are identified regardless of
the investigative method used.
Methodological Remarks
An advantage of this study was the long follow-up period for
patients with stable MCI (mean 5.9 years, range 3.2–8.8), which
makes it the world’s second-longest follow-up study of CSF
biomarkers in MCI patients [44]. Because most MCI patients
convert to dementia within three years, this follow-up should
suffice to ensure reliable diagnostic results [45]. The incidence of
dementia was 13.8% and the incidence of AD was 10.1%, which is
similar to that reported in other studies [46]. Unfortunately, we
lacked some demographic data such as education, family history
and mood disorders, which might have been of value to adjust for
in the regression analyses.
The consensus group of physicians were blinded to the cognitive
test results and CSF data from the initial visit, thus avoiding
circular reasoning during the later analysis of the data. However,
a possible confounder when evaluating cognitive tests as predictors
of AD is that such tests give a measure of cognitive impairment,
which is one of the criteria later used for the diagnosis. This means
that the closer the MCI patients are to dementia (or to more
obvious cognitive impairment), the better the cognitive tests should
be in predicting conversion. If the patients were investigated, say,
two years earlier, it is likely that the prediction accuracy of the tests
would be worse whereas the CSF biomarkers would probably
produce the same results.
The types of dementia diagnosed among the patients with MCI
who developed dementia during follow-up correspond roughly to
the prevalence of different dementia disorders in the community
[47–50]. The result is also consistent with post-mortem studies,
which have shown that a significant subset of patients with MCI
exhibit neuropathological features associated with non-AD
dementias [51–53]. To develop instruments that predict AD with
high specificity in a clinical population, it is therefore important to
include heterogeneous MCI populations, which include other
prodromal dementias than AD.
Conclusions
In this six-year follow-up study of MCI patients, we found that
the MMSE and the clock drawing test were as accurate as the best
combination of CSF biomarkers in identifying patients who will
develop AD. This is the first study to compare these cognitive tests
with CSF biomarkers, and it provides important information
Table 3. Comparison of cognitive tests and CSF biomarkers (logistic regression analysis).
Dependent
variable
Type of independent
variables
Independent variables
in the model OR (95% CI) Correctlyclassified AUC (95% CI)
MCI-AD compared with MCI-
other dementias and stable
MCI
Cognitive tests and CSF MMSE (O & R)
Ab42,208
Tau
Clock drawing ,4p
0.64 (0.55–0.75)
13.3 (3.90–45.2)
1.02 (1.01–1.03)
3.66 (1.19–11.3)
85% 0.93* (0.87–0.96)
CSF Ab42
Tau
Age
0.98 (0.97–0.99)
1.02 (1.01–1.03)
1.02 (1.00–1.05)
83% 0.89 (0.82–0.94)
Cognitive tests MMSE (O & R)
Age
Clock drawing ,4p
0.48 (0.37–0.63)
1.10 (1.06–1.14)
3.46 (1.28–9.31)
81% 0.85 (0.77–0.90)
*p,0.05 compared with AUC for cognitive tests and AUC for CSF. Note that some variable are continuous and others dichotomous, which greatly affects the OR.
The Hosmer and Lemeshow goodness-of-fit test was .0.05 for all models, indicating a good fit of the model to the data.
Demographic variables entered in all models: age and sex; CSF variables entered: Tau, Ab42 or Ab42 dichotomised at ,208 and P-tau; Cognitive test variables entered:
MMSE (orientation & recall) and clock drawing dichotomised at ,4. All were entered with the backward LR method.
AUC = Area under the curve; CI = Confidence interval; MMSE (O & R) = the orientation and delayed word recall parts of the MMSE; MCI-AD = MCI patients who later
convert to AD; MCI-other dementias = MCI patients who later convert to a dementia other than AD; OR = Odds ratio.
doi:10.1371/journal.pone.0038639.t003
Figure 1. AUCs for MCI-AD compared with stable MCI and MCI-
other dementias. The AUCs were derived from the logistic regression
models (Table 3). The AUC from the combined model with both
cognitive tests and CSF biomarkers was significantly better than that of
the CSF model (p=0.04) and the cognitive test model (p=0.01). MMSE
(O & R) = the orientation and delayed word recall parts of the MMSE.
doi:10.1371/journal.pone.0038639.g001
Comparison of Cognitive Tests and CSF in MCI
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38639about the predictive value of brief cognitive tests, especially for
those clinics in which CSF analysis is unavailable. The combina-
tion of CSF and cognitive tests showed significantly greater
accuracy than CSF biomarkers or cognitive tests alone when
predicting AD. The combination therefore provides a small added
diagnostic value.
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